Marta Vaiani Selected Research

Cetuximab (Erbitux)

1/2017

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marta Vaiani Research Topics

Disease

7	Neoplasms (Cancer) 12/2022 - 01/2017
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2017
3	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2017
2	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 02/2015
1	Microsatellite Instability 01/2021
1	Fistula 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 12/2018
1	Thrombosis (Thrombus) 01/2018
1	Fibrosis (Cirrhosis) 05/2017

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2019
1	gadolinium ethoxybenzyl DTPA FDA Link 01/2021
1	Panitumumab (Vectibix)FDA Link 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Bevacizumab (Avastin)FDA Link 01/2019
1	Yttrium-90IBA 01/2018
1	BilirubinIBA 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2017
1	Cetuximab (Erbitux)FDA Link 01/2017
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2017

Therapy/Procedure

4	Therapeutics 12/2022 - 02/2015
2	Drug Therapy (Chemotherapy) 01/2019 - 01/2017
1	Duration of Therapy 01/2021
1	Nephrectomy 12/2018
1	Microspheres (Microsphere) 05/2017
1	Radiofrequency Ablation 01/2017
1	Hepatectomy 01/2017
1	Liver Transplantation 02/2015